Valensa Joins Algae Biomass Organization to Drive Innovation In Microalgae Nutraceuticals

5585952d-1835-4493-a102-50053a308b41articleimage.jpg

15 Jun 2017 --- Valensa International has joined the Algae Biomass Organization (ABO), a major trade association for the algae industry, thereby joining the growing ranks of companies and organizations that are becoming part of the ABO to create awareness about microalgae as a sustainable source of human nutrition, animal feed, water treatment services, chemicals, fuels and countless other products. 

“The ABO’s mission is to ‘promote the development of viable commercial markets’ for products derived from Algae. Valensa is a ‘disruptive innovator’ in microalgae-based nutraceuticals, creating safe, sustainable indication-specific solutions for enhanced health. The power of algae-based nutraceuticals is just emerging on the world scene, and the ABO is getting the word out,” C.P. Umasudhan, CEO at Valensa International, tells NutritionInsight.

“We are excited to have industry leader Valensa join the Algae Biomass Organization’s efforts to expand the availability of algae-based products in dozens of markets,” says Matt Carr, executive director of the ABO. “Valensa’s experience commercializing advanced technologies in human health and nutrition are among the most important for an industry that is just beginning show its potential to provide new products, improve global sustainability, and trigger new economic growth.”

Click to EnlargeHeadquartered in Eustis, Florida, Valensa International is a leading designer of science-based, naturally-sourced proprietary blends of ingredients for nutritional supplements and functional foods. Valensa International holds more than 60 US and International Patents for Formulations and Manufacturing (Deep Extract Supercritical CO2 and O2B Peroxidation Blocker stabilization.) 

“Valensa and affiliate Parry Nutraceuticals have been diligently working on expanding the scope of microalgae production technology including controlled race-way cultures, hybrid closed systems and fermentation technology needed to create safe, efficacious, microalgae-based nutraceuticals,” Umasudhan says. 

Valensa’s scientific team specializes in developing clinical research and intellectual property to introduce unique condition-specific formulations. 

“While applications for microalgae are unlimited, Valensa is producing condition specific algae-based products for eye, cardio and joint health. Valensa’s science team is also working on products that will revolutionize the Immune Health category in both nutraceuticals and functional foods. Retailers and consumers are demanding the next generation in immunity care and the future is promising,” Umasudhan tells NutritionInsight.

Additionally, Valensa has completed clinical work, and continues clinical research, to improve the standard of care in the Immune Health category. Several microalgae approaches have already shown great promise, according to Uma. Valensa is currently in the process of defining microalgae strains and commercialization technology to manufacture algae-derived omega 3 fatty acids (EPA, DHA).

“Exclusive algae-based formulations will become the next generation of nutraceuticals to accommodate growing consumer demand for safe, healthy, sustainable-sourced and all-natural products,” says Umasudhan. “We look forward to building the future of sustainable algae with the support of the ABO.”

“The ABO was created with the overwhelming belief that our future needs lie in the development of microalgae. Some microalgae, like Spirulina, were developed to provide high-quality nutrition to the world. Hybrid open and closed water systems in rural areas, with sustainable production, are set to compete with, or surpass, land or ocean based farming in the near future,” Umasudhan says. 

“The application of spirulina, chlorella and haematococcus pluvialis derived astaxanthin have not yet even scratched the surface of their potential for nutraceutical, functional foods, natural colorant and pharmaceuticals. Valensa, and affiliate Parry Nutraceuticals, are also looking to bring the next generation of plant-based, clean, sustainable omega 3’s to the market. Valensa’s core strategy is to conduct clinical trials and license  intellectual property to enable their customers to sell products that are efficacious and differentiated,” Umasudhan concludes.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Business News

Fermentalg reports on Q1 revenue as US expansion begins

20 Apr 2018 --- Fermentalg, a French supplier of microalgae for nutrition and health, has reported first-quarter revenue of €232k whereas no income was recorded in Q1 2017. As of 31 March 2018, Fermentalg held gross cash and cash equivalents of €19.5 million compared to €21.8 million at 31 December 2017. Cash burn amounted to a €2.5 million outflow, stable compared to the previous quarter (excluding financing activities) and down €0.5 million from Q1 2017. Q1 was marked by progress achieved in bringing to market its DHA ORIGINS range of algal oils naturally rich in omega 3, as well as a US distribution agreement with Stauber, a leading North American supplier of specialty ingredients, the company reports. 

Nutrition & Health News

Omega 3 microalgae oil: Polaris launches “next-generation” solution

09 Apr 2018 --- Polaris, French marine lipid expert, has announced its new omega 3 product: Omegavie DHA 650 Qualitysilver5 (highly concentrated & highly performing omega 3 Algal oil).

Nutrition & Health News

Fermentalg DHA range to enter US market under new partnership

03 Apr 2018 --- French microalgae supplier Fermentalg has obtained Generally Recognized As Safe (GRAS) status for its algal oils which are “naturally rich in omega 3” and they have signed a distribution agreement with Stauber for the US and Canada. These steps represent Fermentalg’ success in driving its DHA origins range on the US market.

Nutrition & Health News

Targeting Asia-Pacific market: Algatech increases reach with Supreme Health partnership

03 Apr 2018 --- Algatechnologies, Ltd. (Algatech) has become the major shareholder in Supreme Health, Ltd., New Zealand, to supply China and Asia-Pacific with astaxanthin and other algae-based products. The Asia-Pacific market for such products is valued at several hundred million dollars, and forecast to experience rapid growth. Israeli-based Algatech specializes in the commercial cultivation of microalgae and manufactures natural astaxanthin, marketed in 35 countries under its AstaPure brand.

Nutrition & Health News

"Uneven playing field": Valensa on fighting fraudulent natural products 

29 Mar 2018 --- Products making false health claims are a blight on the food industry, consumers and of course, manufactures. A case in point is the natural product of Saw Palmetto extract, where six suppliers of the natural drug were found to have “little-to-no actual Saw Palmetto extract,” according to scientists at Valensa International. NutritionInsight spoke to Umasudhan, CEO of Valensa, to gain a deeper insight into this issue, and how battling the fakes fits into the company’s ethical, centralized strategy.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-joins-algae-biomass-organization-to-drive-innovation-in-microalgae-nutraceuticals.html